This week, Cytomedix, Inc. (OTC:CMXI) is moving up. Yesterday, the stock added the next 6.87% to its price, on a traded 
volume of over 85 thousand shares.
The most reasonable explanation on the gain turns out to be the latest news by Cytomedix. The announcements started coming up last week and they still pump up CMXI stock price.
The last piece of news was released just yesterday, when the company reported that is has acquired Aldagen, Inc., a privately-held biopharmaceutical company, in exchange for stock valued at $16 million. The total value of the acquisition was claimed to be $40 million. Along with the new acquisition, Citomedix stated that it was expanding the company’s commitment to the regenerative medicine.
Apparently, the positive statements encouraged traders even more and CMXI stock price reached $1.40 per share. Whether a new uptrend is coming up, is just a matter of time to be seen.
Cytomedix is engaged in the field of advanced tissue regeneration technologies. In December, 2011 and January, 2012, certain members of the company have acquired different amounts of CMXI shares common stock, which immediately influenced the stock volume. Unfortunately, the losses of CMXI remained uncovered.[BANNER]
As of September 30, the company’s cash position was improved, though its liabilities totaled over $8 million. Despite the fact that the revenues of Cytomedix rose up, its accumulated deficit exceeded $52 million, and the net loss to common stockholders got 50% higher as compared to the previous year.
Since inception CMXI has incurred, and continues to incur significant losses from operations. In order to continue operations, the company would likely raise additional capital through the issuance of its equity securities. However, this may result in significant additional dilution to CMXI investors.
